The screening of the second-site suppressor mutations of the common p53 mutants

International Journal of Cancer

Volumn 121, Issue 3, 2007, Pages 559-566

  Otsuka, Kazunori ^a   Kato, Shunsuke ^a   Kakudo, Yuichi ^a   Mashiko, Satsuki ^a   Shibata, Hiroyuki ^a   Ishioka, Chikashi ^a,b  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b NONE   (Japan)

Author keywords

Intragenic suppressor; p53; Second site suppressor mutation; Transactivation

Indexed keywords

COMPLEMENTARY DNA; MUTANT PROTEIN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER SCREENING; CONTROLLED STUDY; DNA LIBRARY; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MISSENSE MUTATION; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SUPPRESSOR GENE; TRANSACTIVATION; YEAST;

APOPTOSIS; CELL LINE, TUMOR; COMPUTER SIMULATION; DNA MUTATIONAL ANALYSIS; GENES, P53; HUMANS; SACCHAROMYCES CEREVISIAE; SUPPRESSION, GENETIC; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 34250800246     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22724     Document Type: Article

References (41)

1. Arrowsmith CH, Morin P. New insights into p53 function from structural studies. Oncogene 1996;12:1379-85.
2. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
3. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenbom AM. Interhelical angles in the solution structure of the oligomerization domain of p53: correction. Science 1995;267:1515-16.
4. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990;249:1046-9.
5. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 1990;249:1049-51.
6. Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995;267:1498-502.
7. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990;5:945-52.
8. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
9. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998;4:839-43.
10. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
11. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-5.
12. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, Thornton JM. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 2002; 19:149-64.
13. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
14. Soussi T, Dehouche K, Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 2000;15:105-13.
15. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003;100:8424-9.
16. Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N, Ishioka C. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 2004;279:348-55.
17. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005;65:2108-14.
18. Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 1998;17:1847-59.
19. Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 2000;19:370-8.
20. Wieczorek AM, Waterman JL, Waterman MJ, Halazonetis TD. Structure-based rescue of common tumor-derived p53 mutants. Nat Med 1996;2:1143-6.
21. Wright JD, Noskov SY, Lim C. Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain. Nucleic Acids Res 2002;30:1563-74.
22. Baroni TE, Wang T, Qian H, Dearth LR, Truong LN, Zeng J, Denes AE, Chen SW, Brachmann RK. A global suppressor motif for p53 cancer mutants. Proc Natl Acad Sci USA 2004;101:4930-5.
23. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem 2005;280:16030-7.
24. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001;1:68-76.
25. Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K, Obinata M, Kanamaru R, Ikawa S, Ishioka C. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 1999;59:2781-6.
26. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S, Iggo R. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 1993;5:124-9.
27. Ishioka C, Englert C, Winge P, Yan YX, Engelstein M, Friend SH. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene 1995;10:1485-92.
28. Ishioka C, Shimodaira H, Englert C, Shimada A, Osada M, Jia LQ, Suzuki T, Gamo M, Kanamaru R. Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. Biochem Biophys Res Commun 1997;232:54-60.
29. Kawaguchi T, Kato S, Otsuka K, Watanabe G, Kumabe T, Tominaga T, Yoshimoto T, Ishioka C. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 2005;24:6976-81.
30. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Electrophoresis 1997;18:2714-23.
31. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000;19:1245-56.
32. Klein C, Planker E, Diercks T, Kessler H, Kunkele KP, Lang K, Hansen S, Schwaiger M. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J Biol Chem 2001;276:49020-7.
33. Rippin TM, Freund SM, Veprintsev DB, Fersht AR. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J Mol Biol 2002;319:351-8.
34. Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski MS, Greenblatt MS. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 1999;18:211-18.
35. Shortle D, Lin B. Genetic analysis of staphylococcal nuclease: identification of three intragenic "global" suppressors of nuclease-minus mutations. Genetics 1985;110:539-55.
36. Haruki M, Noguchi E, Akasako A, Oobatake M, Itaya M, Kanaya S. A novel strategy for stabilization of Escherichia coli ribonuclease HI involving a screen for an intragenic suppressor of carboxyl-terminal deletions. J Biol Chem 1994;269:26904-11.
37. Yamaguchi A, O'Yauchi R, Someya Y, Akasaka T, Sawai T. Second-site mutation of Ala-220 to Glu or Asp suppresses the mutation of Asp-285 to Asn in the transposon Tn10-encoded metal-tetracycline/H+ antiporter of Escherichia coli. J Biol Chem 1993;268:26990-5.
38. Hanson DK, Baciou L, Tiede DM, Nance SL, Schiffer M, Sebban P. In bacterial reaction centers protons can diffuse to the secondary quinone by alternative pathways. Biochim Biophys Acta 1992;1102: 260-5.
39. King SC, Hansen CL, Wilson TH. The interaction between aspartic acid 237 and lysine 358 in the lactose carrier of Escherichia coli. Biochim Biophys Acta 1991;1062:177-86.
40. Iwamoto A, Omote H, Hanada H, Tomioka N, Itai A, Maeda M, Futai M. Mutations in Ser174 and the glycine-rich sequence (Gly149, Gly150, and Thr156) in the beta subunit of Escherichia coli H(+)-ATPase. J Biol Chem 1991;266:16350-5.
41. Kuo PH, Nakamoto RK. Intragenic and intergenic suppression of the Escherichia coli ATP synthase subunit a mutation of Gly-213 to Asn: functional interactions between residues in the proton transport site. Biochem J 2000;347:797-805.